Rising incidence of renal cell cancer in the United States

JAMA

Volumn 281, Issue 17, 1999, Pages 1628-1631

  Chow, Wong Ho ^a   Devesa, Susan S ^a   Warren, Joan L ^a   Fraumeni, Joseph F ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; KIDNEY CARCINOMA; KIDNEY PELVIS CARCINOMA; MALE; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE;

EID: 0033526386     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.281.17.1628     Document Type: Article

References (21)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin. 1998;48:6-29.
2. Devesa SS, Silverman DT, McLaughlin JK, Brown CC, Connelly RR, Fraumeni JF Jr. Comparison of the descriptive epidemiology of urinary tract cancers. Cancer Causes Control. 1990;1:1133-1141.
3. Bretheau D, Lechevallier E, Eghazarian C, Grisoni V, Coulange C. Prognostic significance of incidental renal cell carcinoma. Eur Urol. 1995;5:319-323.
4. Homma Y, Kawabe K, Kitamura T, et al. Increased incidental detection and reduced mortality in renal cancer: recent retrospective analysis at eight institutions. Int J Urol. 1995;2:77-80.
5. Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology. 1998;51:203-205.
6. McCredie M. Bladder and kidney cancers. Cancer Surv. 1994;19:343-368.
7. Ries LAG, Kosary CL, Hankey BF, et al, eds. SEER Cancer Statistics Review, 1973-1995. Bethesda, Md: National Cancer Institute; 1998.
8. Percy C, Van Holten V, Muir C, eds. International Classification of Diseases for Oncology, Second Edition. Geneva, Switzerland: World Health Organization; 1990.
9. Devesa SS, Donaldson J, Fears T. Graphical presentation of trends in rates. Am J Epidemiol. 1995; 141:300-304.
10. McLaughlin JK, Blot WJ, Devesa SS, Fraumeni JF Jr. Renal cancer. In: Schottenfeld D, Fraumeni JF Jr, eds. Cancer Epidemiology and Prevention. 2nd ed. New York, NY: Oxford University Press; 1996:1142-1155.
11. Benichou J, Chow W-H, McLaughlin JK, Mandel JS, Fraumeni JF Jr. Population attributable risk of renal cell cancer in Minnesota. Am J Epidemiol. 1998; 148:424-430.
12. Yuan J-M, Castelao JE, Gago-Dominguez M, Ross RK, Yu MC. Hypertension, obesity and their medications in relation to renal cell carcinoma. Br J Cancer. 1998;77:1508-1513.
13. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obesity. 1998;22: 39-47.
14. Federation of American Societies for Experimental Biology, Life Sciences Research Office. Third Reporton Nutrition Monitoring in the United States: Volume 1. Washington, DC: Interagency Board for Nutrition Monitoring and Related Research; 1995: ES9-ES11.
15. Cross TP, Wise RP, Knapp DE. Antihypertensive drug use: trends in the United States from 1973 to 1985. Hypertension. 1989;13(suppi I):I113-I118.
16. van Zwieten PA. Development and trends in the drug treatment of essential hypertension. J Hypertens. 1992;10(suppl 7):S1-S12.
17. Eisner GM. Hypertension: racial differences. Am J Kidney Dis. 1990;16(suppl 1):35-40.
18. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. W Engl J Med. 1993;328:914-921.
19. Espeland AM, Kumanyika S, Kostis JB, et al. Antihypertensive medication use among recruits for the Trial of Nonpharmacologic Interventions in the Elderly (TONE). J Am Geriatr Soc. 1996;44:1183-1189.
20. Weir MR, Chrysant SC, McCarron DA, et al. Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives. Hypertension. 1998;31:1088-1096.
21. National Center for Health Statistics. Health, United States, 1996-97, and Injury Chartbook. Hyattsville, Md: National Center for Health Statistics; 1997:182-183.